Wuxi NextCODE has been named one of Fast Company’s “Top 10 Most Innovative Companies in Biotech” for being the world’s leading platform for storing, sharing, and interpreting massive sets of genomic data. With offices in Shanghai, Cambridge and Reykjavik, we provide the infrastructure underpinning many of the largest national genome projects and rare disease efforts underway worldwide.

One notable example of our capabilities cited by the editors of Fast Company is the RareCODE rare disease diagnostics platform we launched approximately one year ago in collaboration with Fudan Children’s Hospital in Shanghai. It’s hard to think of work that better taps, according to the magazine’s criteria, “both heartstrings and purse strings and uses the engine of commerce to make a difference in the world.”

RareCODE is the first platform that applies global gold standard genomics to the diagnosis of rare disease, at scale, in China. As a result of this program, Fudan Children’s has been able to quickly and accurately diagnose thousands of rare disease patients, allowing clinicians to optimize their treatment and care.

In just the first calendar year since its launch, RareCODE generated more than 12,000 clinical reports. We and our partners at Fudan also used it for some 2500 cases in their neonatal intensive care unit (NICU). We are now generating more than 1,000 new reports each month.  Thanks to this program, Fudan clinicians have been able to provide diagnoses to nearly 40% of patients tested and recommend treatment for nearly two-thirds of them. In short, this partnership is now carrying out sequencing and delivering diagnoses at a rate that is equivalent to that of the world’s leading laboratories.

We are delighted to join outstanding partners and colleagues on Fast Company’s Top Biotechs list, including Novartis, Biogen, GE Healthcare, Spark Therapeutics, and Sophia Genetics. The winners are selected by the magazine’s reporting team from thousands of enterprises reviewed each year.

Learn more about this award, and the breakthrough genomic platform that helped us earn it.